Physician profile

Sandy Charles

Cardiovascular Disease · Charlotte, NC

NPI 1578706685

$7,339.79

in general payments reported to CMS, 2019-2025

19 companies · $3,000 in 2025

The $3,000 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$5,375.00
Food and Beverage$965.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $5,574.17 2019-2025
E.R. Squibb & Sons, L.L.C. $306.67 2019-2024 Camzyos, Eliquis
Janssen Pharmaceuticals, INC $250.76 2022-2024 Xarelto
Amgen INC. $221.97 2019-2024 Repatha
Esperion Therapeutics, INC. $149.09 2021-2023 Nexletol
Edwards Lifesciences Corporation $142.84 2021
Pfizer INC. $113.96 2022-2024
Alnylam Pharmaceuticals INC. $108.74 2022
Boehringer Ingelheim Pharmaceuticals, INC. $101.54 2022-2024 Jardiance
Heartflow, INC. $76.94 2024
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $66.76 2019-2021
Scpharmaceuticals INC. $43.04 2023-2024
Cvrx, INC. $37.79 2024 Barostim Neo System
Lexicon Pharmaceuticals, INC. $37.58 2023-2024 Inpefa
Genzyme Corporation $28.31 2023
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Kiniksa Pharmaceuticals International, Plc $25.88 2024 Arcalyst
Tactile Systems Technology INC $24.88 2024 Entre Plus, Flexitouch Plus
Lantheus Medical Imaging, INC. $15.11 2019
Medicure Pharma INC. $13.76 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sandy Charles

$7,339.79

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $3,000 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/1353726/sandy-charles

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.